Bio-Rad Laboratories vs Vaxcyte
Bio-Rad Laboratories (BIO), health care, and Vaxcyte (PCVX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Bio-Rad Laboratories is worth $9.6B on the stock market and Vaxcyte $9.4B: Bio-Rad Laboratories is valued at 2% more. Over the past year Bio-Rad Laboratories's share price has moved +17.1% and Vaxcyte's +24.4%.
Key facts
- Bio-Rad Laboratories market value
- $9.6B
- Vaxcyte market value
- $9.4B
- Bio-Rad Laboratories P/E
- 9.5
- Bio-Rad Laboratories revenue
- $2.6BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Bio-Rad Laboratories | Vaxcyte |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $9.6Bhigher | $9.4Blower |
| Revenue | $2.6B | — |
| Earnings | $759.9Mhigher | -$766.6Mlower |
| Employees | 7,450higher | 507lower |
| Total assets | $10.6Bhigher | $3Blower |
| Valuation | ||
| P/E | 9.5 | — |
| P/S | 3.7 | — |
| P/B | 1.3lower | 3.6higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 1.83% | — |
| Balance sheet | ||
| Net assets | $7.5Bhigher | $2.7Blower |
| Total liabilities | $3.1Bhigher | $317.2Mlower |
| Total debt | $1.2B | — |
| Cash on hand | $529.8Mhigher | $174Mlower |
| Price change | ||
| Today | -0.57%higher | -3.59%lower |
| 1 year | +17.1%lower | +24.4%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Bio-Rad Laboratories only (3)
- John Rogers3.1%
- Matthew McLennan1.5%
- Steven Romick1.2%
Vaxcyte only (2)
- Peter Kolchinsky5.8%
- Lee Ainslie0.8%
Percentages are each holding's share of that investor's reported portfolio. Who owns BIO · Who owns PCVX
More on Bio-Rad Laboratories
Further comparisons
Bio-Rad Laboratories against its closest peers
Vaxcyte against its closest peers
Learn
Questions and answers
Which is bigger, Bio-Rad Laboratories or Vaxcyte?
By market value, Bio-Rad Laboratories is the larger: $9.6B against $9.4B for Vaxcyte.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Bio-Rad Laboratories and Vaxcyte?
None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Bio-Rad Laboratories and 2 hold Vaxcyte.
Cite this page
Funkfolio, “Bio-Rad Laboratories vs Vaxcyte”, data as of 17 November 2026. https://funkfolio.com/compare/bio-vs-pcvx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.